Journal of Bone and Mineral Metabolism

, Volume 32, Issue 6, pp 606–615 | Cite as

Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials

Review Article

Abstract

Bisphosphonates are potent inhibitors of bone resorption, widely used for the management of osteoporosis and fracture prevention. Recent evidence suggests that bisphosphonates may have beneficial effects in the treatment of thalassemia-associated osteoporosis, a complex and multifactorial condition. Here we summarise available data about the efficacy and tolerability of bisphosphonates in beta-thalassemic patients. Randomised controlled trials (RCTs) of bisphosphonates in beta-thalassemia were identified searching PubMed. Studies were reviewed to retrieve relevant clinical information. The following variables were considered to assess the safety and efficacy of bisphosphonates—bone mineral density (BMD), markers of bone turnover, incidence of fragility fracture, bone pain, back pain, and clinical adverse events. Five RCTs were identified, investigating alendronate, clodronate, zoledronic acid and neridronate. All bisphosphonates produced a significant decrease of the markers of bone turnover. Alendronate, neridronate, and zoledronic acid significantly improved BMD at the lumbar spine, femoral neck and total hip. Zoledronic acid and neridronate were also shown to reduce bone and back pain. Probably due to the small sample sizes and to the short duration of the trials, it was not possible to establish the anti-fracture efficacy of bisphosphonates; however, they were well tolerated and adverse events were rare but expected on the basis of previous studies. Sufficient evidence exists to support the use of bisphosphonates in the management of thalassemia-associated osteoporosis (to prevent bone loss and improve the BMD). Further research is warranted to establish their anti-fracture efficacy and long-term safety.

Keywords

Bisphosphonates Thalassemia Osteoporosis Fractures 

Notes

Conflict of interest

Dr Giusti serves as consultant for Dynamicom (CME provider, Milano, Italy), Merck & Co. and Eli Lilly.

References

  1. 1.
    Galanello R, Origa R (2010) Beta-thalassemia. Orphanet J Rare Dis 5:11PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Forni GL, Puntoni M, Boeri E, Terenzani L, Balocco M (2009) The influence of treatment in specialized centers on survival of patients with thalassemia major. Am J Hematol 84:317–318PubMedCrossRefGoogle Scholar
  3. 3.
    Voskaridou E, Terpos E (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 127:127–139PubMedCrossRefGoogle Scholar
  4. 4.
    Haidar R, Musallam KM, Taher AT (2011) Bone disease and skeletal complications in patients with β thalassemia major. Bone 48:425–432PubMedCrossRefGoogle Scholar
  5. 5.
    Vogiatzi MG, Macklin EA, Fung EB et al (2009) Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 24:543–557PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Fung EB, Harmatz PR, Milet M, Multi-Center Iron Overload Study Group et al (2008) Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone 43:162–168PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Vogiatzi MG, Macklin EA, Fung EB et al (2006) Prevalence of fractures among the thalassemia syndromes in North America. Bone 38:571–575PubMedCrossRefGoogle Scholar
  8. 8.
    Wonke B, Jensen C, Hanslip JJ et al (1998) Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 11:795–801PubMedGoogle Scholar
  9. 9.
    Wonke B (1998) Bone disease in beta-thalassaemia major. Br J Haematol 103:897–901PubMedCrossRefGoogle Scholar
  10. 10.
    Morabito N, Gaudio A, Lasco A et al (2004) Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 19:722–727PubMedCrossRefGoogle Scholar
  11. 11.
    Papapoulos SE (2011) Use of bisphosphonates in the management of postmenopausal osteoporosis. Ann N Y Acad Sci 1218:15–32PubMedCrossRefGoogle Scholar
  12. 12.
    Papapoulos SE (2008) Bisphosphonates: how do they work? Best Pract Res Clin Endocrinol Metab 22:831–847PubMedCrossRefGoogle Scholar
  13. 13.
    Giusti A, Papapoulos SE (2009) Treatment of male osteoporosis with bisphosphonates. In: Orwoll ES, Bilezikian JP, Vanderschueren D (eds) Osteoporosis in men: the effects of gender on skeletal health, 2nd edn. Academic Press (Elsevier), London, pp 667–679Google Scholar
  14. 14.
    Rizzoli R, Reginster JY, Boonen S et al (2011) Adverse reactions and drug–drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 89:91–104PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Khosla S, Burr D, Cauley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491PubMedCrossRefGoogle Scholar
  16. 16.
    Giusti A, Hamdy NA, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 47:169–180PubMedCrossRefGoogle Scholar
  17. 17.
    Morabito N, Lasco A, Gaudio A et al (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 13:644–649PubMedCrossRefGoogle Scholar
  18. 18.
    Pennisi P, Pizzarelli G, Spina M, Riccobene S, Fiore CE (2003) Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. J Bone Miner Metab 21:402–408PubMedCrossRefGoogle Scholar
  19. 19.
    Voskaridou E, Anagnostopoulos A, Konstantopoulos K et al (2006) Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica 91:1193–1202PubMedGoogle Scholar
  20. 20.
    Gilfillan CP, Strauss BJ, Rodda CP et al (2006) A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int 79:138–144PubMedCrossRefGoogle Scholar
  21. 21.
    Forni GL, Perrotta S, Giusti A et al (2012) Neridronate improves bone mineral density and reduces back pain in beta-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study. Br J Haematol 158:274–282PubMedCrossRefGoogle Scholar
  22. 22.
    Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93:1588–1590PubMedCrossRefGoogle Scholar
  23. 23.
    Voskaridou E, Christoulas D, Antoniadou L, Terpos E (2008) Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis. Acta Haematol 119:40–44PubMedCrossRefGoogle Scholar
  24. 24.
    Voskaridou E, Christoulas D, Plata E et al (2012) High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res [Epub ahead of print]Google Scholar
  25. 25.
    Voskaridou E, Christoulas D, Xirakia C et al (2009) Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 94:725–728PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Mamtani M, Kulkarni H (2010) Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review. Osteoporos Int 21:183–187PubMedCrossRefGoogle Scholar
  27. 27.
    Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedCrossRefGoogle Scholar
  28. 28.
    Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMedCrossRefGoogle Scholar
  29. 29.
    Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443PubMedCrossRefGoogle Scholar
  30. 30.
    Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468PubMedCrossRefGoogle Scholar
  31. 31.
    Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedCrossRefGoogle Scholar
  32. 32.
    McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRefGoogle Scholar
  33. 33.
    Reginster JY, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91PubMedCrossRefGoogle Scholar
  34. 34.
    Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRefGoogle Scholar
  35. 35.
    Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRefGoogle Scholar
  36. 36.
    Lyles KW, Colón-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRefGoogle Scholar
  37. 37.
    Brumsen C, Papapoulos SE, Lips P et al (2002) Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 17:1057–1064PubMedCrossRefGoogle Scholar
  38. 38.
    McCloskey E, Selby P, Davies M et al (2004) Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19:728–736PubMedCrossRefGoogle Scholar
  39. 39.
    McCloskey EV, Beneton M, Charlesworth D et al (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo controlled randomized study. J Bone Miner Res 22:135–141PubMedCrossRefGoogle Scholar
  40. 40.
    Coleman R, de Boer R, Eidtmann H et al (2012) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol [Epub ahead of print]Google Scholar
  41. 41.
    Llombart A, Frassoldati A, Paija O et al (2012) Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 12:40–48PubMedCrossRefGoogle Scholar
  42. 42.
    Brufsky AM, Harker WG, Beck JT et al (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118:1192–1201PubMedCrossRefGoogle Scholar
  43. 43.
    Varenna M, Bertoldo F, Di Monaco M, Giusti A, Martini G, Rossini M (2013) Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature. Reumatismo 65:143–166PubMedCrossRefGoogle Scholar
  44. 44.
    Grey A, Bolland MJ, Horne A et al (2012) Five years of anti-resorptive activity after a single dose of zoledronate: results from a randomized double-blind placebo-controlled trial. Bone 50:1389–1393PubMedCrossRefGoogle Scholar
  45. 45.
    Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243–254PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRefGoogle Scholar
  47. 47.
    Chatterjee R, Shah FT, Davis BA et al (2012) Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. Br J Haematol 159:462–471PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan 2014

Authors and Affiliations

  1. 1.Department of Gerontology and Musculoskeletal SciencesGalliera Hospital, ASL3GenoaItaly

Personalised recommendations